Dr. Chung-Han Lee discusses ongoing pembrolizumab/lenvatinib trial in non-clear cell RCC

First study author Chung-Han Lee, MD, PhD, discusses the ongoing open-label phase 2 KEYNOTE-B61 study of frontline pembrolizumab (Keytruda) plus lenvatinib (Lenvima) in non-clear cell renal cell carcinoma. Lee, a medical oncologist at Memorial Sloan Kettering Cancer Center, shared a poster highlighting this study as part of the trials in progress session at the 2021 ASCO Annual Meeting.